Sweden-headquartered Genovis AB (GENO.ST), a provider of innovative enzyme technologies, on Thursday announced an expansion of its license agreement with U.S.-based Thermo Fisher Scientific Inc. (TMO).
The agreement provides access to proprietary enzyme technology to develop and manufacture antibody-drug conjugates intended for therapeutic use. This broadens the scope of the original license agreement which was previously limited to discovery and preclinical research.
Financial details of the transaction have not been disclosed.
Genovis expects the expansion of the license to therapeutic applications to help in the advancement of promising ADC candidates into clinical development and, ultimately, the market. It is also seen as a significant step forward to help enable innovative targeted cancer therapies.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.